(2S)-5-methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine,hydrochloride

We are (2S)-5-methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine,hydrochloride CAS:93601-86-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(2S)-5-methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine,hydrochloride
CAS.NO:93601-86-6
Synonyms:(2S)-5-methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine,hydrochloride
(S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-ammonium hydrochloride
(S)-5-Methoxy-N-propyl-2-Aminotetralin Hydrochloride
(S)-(-)-(5-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamine hydrochloride
(S)-5-methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine hydrochloride
(-)-5-methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine hydrochloride
 
Physical and Chemical Properties:
Molecular Formula C14H22ClNO
Molecular Weight 255.784
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Rotigotine(CAS:99755-59-6/92206-54-7).

(2S)-5-methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine,hydrochloride


Related News: Inceptua has global operations with local offices across Europe, USA, and Asia8-fluorooctan-1-ol CAS:408-27-5 Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs.5-Bromo-2,4-difluorotoluene CAS:159277-47-1 Multinational drugmakers usually cut the price of drugs when they go off-patent and face competition from generic versions, but such price drops were slow to happen in China, partially because many local drugmakers were unable to develop high-quality generic drugs to compete with off-patent branded drugs.4-Fluorobenzylamine The company’s pharmaceutical intermediate business is expected to maintain a growth rate of more than 30%.Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,” said Mark Corbett, EVP, Inceptua Medicines Access.

Related Products
Product Name
3-Bromo-2-fluoro-5-methylpyridine View Details
Tetraethyl orthosilicate hydrolyzed View Details
(E)-4-(Dimethylamino)But-2-Enoic Acid Hydrochloride View Details
Ethyl (R)-(+)-4-Chloro-3-Hydroxybutyrate manufacturer Light Stabilizer 66 manufacturer 2-Bromo-5-(trifluoromethyl)pyridine manufacturer [dimethyl-[3-(oxiran-2-ylmethoxy)propyl]silyl]oxy-dimethyl-[3-(oxiran-2-ylmethoxy)propyl]silane manufacturer D-Homophenylalanine manufacturer